Vyleesi International Purchase: What Women Need to Know About Buying Bremelanotide Outside the US

What Is Vyleesi and Who Is It Actually For?

Bremelanotide, sold as Vyleesi, is a melanocortin receptor agonist that acts on MC4 receptors in the central nervous system to increase sexual desire. It is the second FDA-approved pharmacotherapy for HSDD in premenopausal women, following flibanserin (Addyi), which was approved in 2015.

The FDA approved bremelanotide on June 21, 2019, specifically for premenopausal women with acquired, generalized HSDD, defined as low sexual desire that causes marked distress, was not present from the start of sexual activity, and occurs regardless of partner or situation. That framing matters. The approval is narrow on purpose.

The Life-Stage Boundary Is a Hard Line

The clinical trials that earned bremelanotide its approval, primarily the RECONNECT studies published in 2019, enrolled premenopausal women aged 21 to 57. Postmenopausal women were excluded. The FDA label explicitly states that efficacy and safety have not been established in postmenopausal women, and the drug is not approved for that population.

If you are in perimenopause, the picture is complicated. Your cycle may be irregular, your estrogen is declining, and your HSDD may have a different hormonal driver than the trial participants. No dedicated perimenopausal subgroup data from the RECONNECT studies has been published. If your clinician considers Vyleesi during perimenopause, that is off-label use, and you deserve a clear conversation about what the evidence does and does not cover.

HSDD in Women: The Broader Context

HSDD is not rare. Estimates suggest roughly 10 percent of premenopausal women meet diagnostic criteria for HSDD with associated distress, though prevalence figures vary depending on how distress is measured. The condition is more common than most women realize, and it intersects with several conditions WomanRx covers regularly: thyroid dysfunction, PCOS-related androgen changes, postpartum hormonal shifts, and the estrogen decline of perimenopause.

International Regulatory Status of Bremelanotide

Vyleesi is approved for use only in the United States. Palatin Technologies has not received marketing authorization from the European Medicines Agency (EMA), Health Canada, the UK's Medicines and Healthcare products Regulatory Agency (MHRA), the Therapeutic Goods Administration (TGA) in Australia, or any other major regulatory body outside the US as of early 2026.

That single fact drives every legal question about international purchase.

Why No Other Country Has Approved It

Drug approval requires the manufacturer to submit a dossier and seek marketing authorization in each jurisdiction. Palatin has not done this for bremelanotide in most countries. The reasons are commercial, not necessarily scientific. But the practical consequence for you is that a pharmacy operating legally in the UK, Canada, Germany, or Australia cannot legally dispense Vyleesi, because it has no authorization there.

What "Gray Market" Actually Means

You may find online pharmacies, compounding operations, or grey-market vendors claiming to sell "bremelanotide" or "PT-141" (the peptide research name for bremelanotide) internationally. These sources are not selling the FDA-approved Vyleesi product. They are selling either:

• Compounded bremelanotide of unknown purity, sterility, and concentration
• Research-grade peptide, labeled "not for human use" to sidestep pharmaceutical regulations
• Counterfeit or mislabeled product

None of these is the same as the pharmaceutical-grade 1.75 mg auto-injector that went through the RECONNECT trial. The difference is not academic. Peptide purity, sterility of the injection vehicle, and accurate dosing all affect both efficacy and safety.

Personal Importation: The US FDA Rule

The FDA has a personal importation policy that allows, in limited circumstances, an individual to import a 90-day supply of a drug for personal use when there is no comparable US-approved alternative and the drug poses no unreasonable risk. Bremelanotide fails that test. There is a US-approved alternative, Vyleesi itself, so personal importation of a foreign version cannot meet the "no US equivalent" criterion. FDA enforcement is discretionary, and a single injector in checked luggage is unlikely to trigger a customs seizure. However, the legal footing is weak, and any claimed "safe harbor" for personal importation does not apply here.

The Compounded Bremelanotide / PT-141 Question

Compounded bremelanotide, often marketed online under the peptide name PT-141, occupies a separate and more complicated regulatory space than the international pharmacy question. Here is a practical framework for thinking through this:

| Source type | Legal status | Purity guarantee | Your clinical recourse if something goes wrong | |---|---|---|---| | US licensed compounding pharmacy (503A, physician prescription required) | Legal under state pharmacy law; not FDA-approved | Varies; no mandatory batch testing | File a complaint with state board; limited | | 503B outsourcing facility | Federally registered; higher standards | Batch-tested, COA available | FDA oversight applies | | Online "research peptide" vendor | Not legal for human use; sold to circumvent regulation | Unknown; contamination documented in literature | None | | International online pharmacy (no Vyleesi authorization) | Illegal in the country of origin and/or US importation | Unknown | None |

The FDA has issued multiple warning letters to compounders selling peptides including melanocortin-related compounds for human use without a prescription. The risk is real.

What 503A Compounding Actually Requires

A licensed 503A compounding pharmacy in the US can prepare bremelanotide for a specific patient under a valid prescription from a licensed practitioner. The drug must be compounded in response to a prescription for an individual patient, not manufactured in bulk for general sale. If a vendor offers to ship you bremelanotide without a US prescription, it is operating outside this legal framework regardless of where it is located.

How to Get Vyleesi at a Lower Cost in the US

Given that international purchase carries legal and safety risks, your best path to affordable bremelanotide runs through US-based programs. Several options exist, and they stack differently depending on your insurance status.

Manufacturer Patient Assistance

Palatin Technologies partnered with AMAG Pharmaceuticals (now acquired by Covis Pharma) for Vyleesi's commercialization. The Vyleesi savings card program has historically offered commercially insured patients significant reductions in co-pay. Programs change frequently; call the Vyleesi support line (listed on the prescribing information) or ask your pharmacist to verify current terms before your prescription is filled.

Women who are uninsured or underinsured may qualify for patient assistance through the manufacturer. Income thresholds apply. A social worker at a women's health clinic or your prescriber's office can help you apply.

Insurance Coverage and Prior Authorization

Most commercial insurance plans classify Vyleesi as a specialty drug requiring prior authorization. Your prescriber will need to document that you meet the diagnostic criteria for HSDD, that the desire problem is acquired and generalized, and that it causes clinically meaningful distress. Some plans require a trial or documented failure of a psychotherapeutic approach first. ACOG has noted that HSDD evaluation should include assessment for contributing medical and psychological factors before pharmacotherapy, which aligns with what most insurers require anyway.

HSA and FSA

Yes, Vyleesi is eligible for payment with a Health Savings Account (HSA) or Flexible Spending Account (FSA). Under IRS rules, prescription drugs qualify as a medical expense for HSA/FSA purposes. Because Vyleesi requires a prescription, your out-of-pocket cost at a licensed US pharmacy can be paid with HSA or FSA funds. Keep your receipt and prescription documentation. Over-the-counter bremelanotide from a non-pharmacy source would not qualify, both because it would lack a valid prescription and because it likely does not meet the requirement for an FDA-approved drug.

GoodRx, Mark Cuban's Cost Plus Drugs, and Coupon Aggregators

GoodRx lists bremelanotide at several pharmacy chains. Prices fluctuate. As of late 2025, GoodRx prices have appeared in the $600 to $750 range per carton at some chains, which may be lower than your insurance co-pay depending on your plan. Cost Plus Drugs (Mark Cuban's pharmacy) does not currently list bremelanotide, which is consistent with specialty injectable drugs generally not appearing on that platform.

Coupon use at a pharmacy is legal and does not affect your prescription validity. However, using a coupon may make the purchase ineligible for application toward your insurance deductible. Weigh that trade-off.

Telehealth Prescribing Within the US

Several US telehealth platforms now offer HSDD evaluation and, where clinically appropriate, bremelanotide prescribing. Telehealth prescribing for controlled substances has specific federal rules, but bremelanotide is not a controlled substance. A synchronous or asynchronous telehealth visit can generate a valid US prescription that you fill at a licensed US pharmacy. This does not reduce the drug's list price, but it removes the barrier of an in-person appointment if access is limited where you live.

Sex-Specific Pharmacology: How Bremelanotide Works Differently in Women

Bremelanotide's mechanism, agonism at central melanocortin MC3 and MC4 receptors, is relevant to why the drug was studied specifically in women with HSDD rather than as a general sexual dysfunction treatment.

Hormonal Status Changes the Response

The RECONNECT trials enrolled women on stable hormonal contraception and women not using hormonal contraception, and both groups showed statistically significant improvements in desire. However, the trial did not stratify by menstrual cycle phase. Animal data suggest MC4 receptor sensitivity may vary with estrogen levels. One preclinical study found that estrogen priming enhanced bremelanotide-induced sexual behavior in female rats, which raises the question of whether low-estrogen states (late luteal phase, perimenopause) attenuate the response. This has not been studied systematically in women. The data gap is real.

Nausea Is the Dose-Limiting Side Effect and It Hits Women Hard

In RECONNECT, nausea occurred in 40.4 percent of women using bremelanotide versus 1.4 percent on placebo. It is the primary reason women discontinue the drug. Nausea typically peaks 30 to 60 minutes after injection and resolves within 2 hours. Eating a low-fat meal before injection and avoiding alcohol may reduce severity. The prescribing information recommends no more than one injection in 24 hours and limiting use to approximately 8 doses per month, though no formal frequency cap appears in the label.

Women with a history of severe nausea in pregnancy (hyperemesis gravidarum) may be more susceptible, though this is clinical inference rather than trial data.

Transient Blood Pressure Increase

Bremelanotide transiently increases blood pressure and decreases heart rate. In the RECONNECT studies, mean systolic BP increased approximately 1.7 mmHg and mean diastolic BP by approximately 1.5 mmHg. The label carries a contraindication for women with known cardiovascular disease and warns against use in uncontrolled hypertension. If you have any personal history of hypertension, pre-eclampsia, or cardiac arrhythmia, discuss this explicitly with your prescriber before the first dose.

Pregnancy, Lactation, and Contraception

Bremelanotide is contraindicated in pregnancy. This is not a precautionary warning based on theoretical risk. The FDA label is explicit.

Pregnancy Data

Animal reproduction studies showed fetal harm at doses approximating human exposure. The prescribing information states that bremelanotide increased the incidence of fetal malformations in rats and mice. There are no adequate and well-controlled studies in pregnant women, and there are not likely to be any, given standard ethical constraints. Because of the animal data and the absence of human safety evidence, bremelanotide should not be used if you are pregnant or attempting to conceive.

The indication itself (premenopausal, non-pregnant women with HSDD) presupposes that pregnancy is not the goal at the time of use. If you are trying to conceive, you should stop bremelanotide and discuss the HSDD with your reproductive endocrinologist or OB-GYN, who can address contributing factors in the context of fertility treatment.

Lactation

No data exist on bremelanotide transfer into human milk. Animal studies have not been conducted for lactation specifically. The FDA label advises that because of the potential for adverse effects in the nursing infant, breastfeeding is not recommended during bremelanotide use. If low sexual desire is a concern in the postpartum period, which is extremely common given prolactin's libido-suppressing effects and the demands of new parenthood, discuss non-pharmacologic approaches and whether postpartum hormonal status is a contributing factor before considering bremelanotide.

Contraception Requirement

Because the drug is contraindicated in pregnancy and because unintended pregnancy can occur in premenopausal women using any method of contraception with less than perfect efficacy, ensure your contraceptive plan is reliable if you are using bremelanotide. Bremelanotide does not appear to meaningfully interact with combined oral contraceptives at the pharmacokinetic level, but the label notes that systemic exposure to some drugs may be affected because bremelanotide slows gastric emptying. If you rely on an oral pill taken around the time of a dose, take the pill at least 1 hour before the bremelanotide injection.

Who This Is and Is Not Right For

Most Likely to Benefit

• Premenopausal women with a documented pattern of reduced sexual desire that is acquired (developed after a period of normal desire), generalized (not partner- or situation-specific), and causing personal distress
• Women who have already addressed contributing factors such as relationship conflict, depression, thyroid dysfunction, or androgen deficiency from PCOS treatment, and still have significant HSDD
• Women who tried flibanserin (Addyi) and found daily dosing inconvenient or poorly tolerated
• Women who prefer an as-needed injection over a daily oral medication

Less Likely to Benefit or Should Avoid

• Postmenopausal women (not approved; genitourinary syndrome of menopause and estrogen decline may be the primary driver and should be addressed first)
• Pregnant women (contraindicated)
• Breastfeeding women (avoid; insufficient data)
• Women with uncontrolled hypertension or cardiovascular disease (contraindicated)
• Women whose low desire is situational (related to a specific partner or context) rather than generalized
• Women with a primary psychiatric diagnosis such as major depression that is undertreated; addressing the mood disorder often resolves HSDD

"The distinction between acquired generalized HSDD and situational low desire matters enormously for treatment selection," says WomanRx medical reviewer Elena Vasquez, MD. "Bremelanotide works centrally on desire circuitry. If the problem is relational, contextual, or driven by undertreated perimenopause, you are asking the wrong tool to do the job. An honest clinical assessment before prescribing prevents disappointment and avoidable side effects."

Evidence Gaps Women Should Know About

Women have been historically underrepresented in clinical trial design and in sexual health research specifically. The RECONNECT studies were conducted entirely in women, which is appropriate for an HSDD indication, but the evidence base has notable gaps:

• No head-to-head trial comparing bremelanotide to flibanserin exists. Choosing between them relies on indirect comparison and clinical judgment.
• Perimenopausal women were excluded. If your cycles are irregular and your FSH is rising, you are navigating extrapolated rather than direct evidence.
• No long-term safety data beyond 52 weeks are published. RECONNECT followed women for 52 weeks. Lifetime risk of repeated transient blood pressure elevations from periodic use is not characterized.
• Racial and ethnic diversity in the RECONNECT trials was limited. The published trial reported approximately 84 percent white participants. Whether efficacy and side-effect profiles differ by race or ethnicity is unknown.
• Women with PCOS were not studied as a subgroup. PCOS affects approximately 8 to 13 percent of reproductive-age women and involves androgen excess that complicates desire physiology. No PCOS-specific data exist for bremelanotide.

Practical Steps If You Are Considering Vyleesi

1. See a licensed US clinician, in person or via telehealth, who can evaluate whether your sexual desire change meets the acquired, generalized, distressing criteria that define HSDD.
2. Rule out contributing factors first: thyroid function, depression, relationship dynamics, pelvic pain, androgen levels if clinically relevant.
3. If bremelanotide is appropriate, get a prescription from your US clinician and fill it at a licensed US pharmacy.
4. Ask your pharmacist about the manufacturer savings program and check GoodRx pricing before filling. Compare both to your insurance co-pay.
5. If you have an HSA or FSA, confirm your account administrator accepts prescription drug purchases (virtually all do) and save your receipt.
6. Inject the 1.75 mg dose subcutaneously in the abdomen or thigh approximately 45 minutes before anticipated sexual activity. Do not use more than once per 24-hour period.
7. If nausea is severe, contact your prescriber. Do not attempt to self-adjust your dose or purchase a lower-concentration compounded version without medical guidance.

Buying bremelanotide from an international online pharmacy or a research peptide vendor does not save you money in any meaningful sense when you account for the absence of dose guarantees, no recourse if the product is contaminated, the legal risk of importation, and the absence of any pharmacovigilance system to catch problems. The FDA's MedWatch program exists specifically to catch post-approval safety signals. It only works when women using the actual approved product report adverse events.